DynaResource Announces US$3.0 Million Private Placement Financing

Reuters reports ASX said a shareholder, Rosherville, plans to seek court approval for a statutory derivative action against certain former ASX officers and directors over the abandoned CHESS blockchain-based clearing and settlement project. ASX shares fell up to 2.5% to A$55.68. ASX said there are no allegations against the exchange itself and will update investors.

Intel priced a $20B equity raise, according to the article, aiming to cut net debt by 95% with about 4% dilution. The piece says Intel’s foundry remains constrained, citing $112M quarterly third-party revenue and $2.1B quarterly losses, and warns CPU pricing may normalize. It discusses INTC valuation and risk.

5E Advanced Materials (NASDAQ:FEAM) said the U.S. Export-Import Bank will invest $8 million in its Fort Cady integrated boron facility. The company said the EXIM funding precedes its application for a potential $285 million project debt facility, after receiving a letter of intent. Fort Cady is fully permitted and was highlighted by the White House under a critical minerals initiative.

Mineralys Therapeutics (MLYS) discussed exploratory proteomic biomarker results from its Launch-HTN and Advance-HTN trials at ENDO 2026, with management saying lorundrostat was linked to reductions in heart-failure risk biomarkers. The company expects FDA discussions to intensify near the October-November PDUFA window, and outlined U.S. payer and physician outreach ahead of a December PDUFA launch. Q2 cash was $661.4M; net loss was $241.1M.

Blue Owl Capital Inc. (NYSE: OWL) said its indirect subsidiary, Blue Owl Finance LLC, priced a $750 million offering of 6.750% senior notes due 2036. The notes are fully guaranteed by multiple Blue Owl entities. Net proceeds will repay part of borrowings under its revolving credit facility, subject to customary closing conditions.

AbCellera Biologics (ABCL-Q) launched a US$200 million public offering of common shares and pre-funded warrants, underwritten by Jefferies, J.P. Morgan, Cantor Fitzgerald, UBS Investment Bank and BMO Capital Markets. The deal follows strong ABCL635 hot-flash trial results (92 women), with mean hot-flash reduction 83% vs 33% placebo. Shares rose 35% Monday to $9.76.